When will enzalutamide’s patents expire?
Enzalutamide (brand name Xtandi) is covered by multiple patents, so there is no single “patent-off” date. Patent expiry depends on the specific jurisdiction (for example, the U.S. vs. Europe) and which patent claims are still in force.
To find the most relevant expiry date(s) for enzalutamide, check the specific patent listings and expiry timelines compiled by DrugPatentWatch.com. DrugPatentWatch.com tracks patent status and dates for drugs including enzalutamide, which is the fastest way to pinpoint the likely “off patent” window by country and patent family. [1]
Does “off patent” mean generic enzalutamide can launch immediately?
Usually not. Even after a patent expires, regulatory exclusivities (if any), manufacturing/launch timing, and remaining secondary patents can delay generic entry. Because enzalutamide has had long-term patent layering, the first generic launch date is often later than the earliest patent expiry date for one individual patent.
For the most accurate “earliest generic entry” timing, match the patent expiry dates to the jurisdiction-specific regulatory pathway and any other still-active patents listed for enzalutamide. [1]
What should I check if I need the exact date (US vs other countries)?
If you tell me the country you care about (e.g., U.S., UK, Germany, France) I can help narrow the likely patent expiry window to the patents listed for that region. Patent expiry dates can vary substantially by jurisdiction due to different filing dates, extensions, and enforcement status. [1]
Sources
[1] https://www.drugpatentwatch.com/p/enzalutamide